BGOG-ov-55

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Sponsor: ImmunoGen

Participating sites:

  • Hôpital de Libramont, Libramont
  • UZ Leuven, Leuven
  • OLV Aalst, Aalst
  • UZ Antwerpen, Antwerpen
  • AZ Sint Lucas, Gent
  • AZ Klina, Roeselare